Symrise

On 29.10.2026 Symrise executive board member Ribeiro purchased 500 shares at a price of 92.76 EUR, reported on 30.10.2026. The filing contributed to a rise in the share price in FSE trading; the price at times reached around 92.10 EUR (+3.00%). Earlier, executives on 28.10.2026 had already bought 393 shares at 89.70 EUR. » More on finanzen.net

Board member Michael Friede bought 393 Symrise shares at €89.70 each on the day of the sell-off; it is his third purchase since May, with around €135,700 invested in total. The stock fell despite strong quarterly figures because Symrise confirmed adjusted EBITDA guidance in the lower half of the target range and moderate organic growth. Analysts remained mostly positive; the purchases are seen as a personal vote of confidence in Friede’s Scent & Care segment but carry limited significance for the stock’s performance. » More on finanzen.net

On 28 October 2026 BaFin reported that executive board member Michael Friede increased his stake in Symrise by 393 shares at EUR 89.70 each. The disclosure weighed on the stock, which at the FSE close fell 7.20 percent to EUR 88.96. Friede had already topped up his portfolio on 15 September 2026 by 566 units at EUR 89.10 each. » More on finanzen.net

In a study, DZ BANK keeps its rating on Symrise at "buy" and names a fair value of €105. Symrise beat the company-calculated consensus in the third quarter, but investors reacted to the competitor Givaudan’s figures with disappointment. On the day of the analysis the stock fell about 10.2% in XETRA trading to €89.80, but it is still up 32.6% year-to-date. » More on finanzen.net

Symrise shares posted a 9.8 percent decline, the biggest daily loss in the Dax, despite a surprisingly strong third quarter. The group cut its full‑year forecast for organic growth to around three percent, below analysts’ expectations, which triggered the selling pressure. » More on handelsblatt.com